Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
about
Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study.Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.Adherence to Antipsychotic Medication and Criminal Recidivism in a Canadian Provincial Offender Population.Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Three-month paliperidone palmitate - a new treatment option for schizophrenia.Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder.Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Risperidone reverses the spatial object recognition impairment and hippocampal BDNF-TrkB signalling system alterations induced by acute MK-801 treatment.Perceptions and knowledge of antipsychotics among mental health professionals and patients.A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia.The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Imagining schizophrenia without relapses.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.Claims-based proxies of patient instability among commercially insured adults with schizophrenia.Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2.Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
P2860
Q30490166-F8E342A4-B12B-4388-9BC2-D618F1B25C9BQ35912043-FC188A4F-734F-4BBF-9267-85ED10FBBA2FQ36852406-FC105040-D9BB-49AC-9945-12716D42E90BQ37388354-7F4C7021-2A95-489B-849A-9598B896451FQ38403164-A68BBB6C-3CC8-47B8-800C-B8D45B6C9230Q38659006-E2F95FAC-5C42-4669-9BBB-52902A9EB1C3Q38668405-65D5ED3D-4CF9-4FE1-8575-C507653BB177Q38728652-725EE6AD-CDFB-4246-8F65-EB110DC0778EQ38737194-DB340CDA-81D4-417F-BBD8-E5F77F92C86BQ38744570-B8ACB1DD-F67E-4083-ADED-A1B48E005386Q38840088-2E631993-11C7-430D-AA04-04BA99BF7DF7Q38851123-643DF9E7-76C0-489D-91B3-EDD69F09B640Q38851847-66B42783-4428-470B-AF83-BD5BFB9650EDQ39073819-9FCFD3DB-C112-4080-A528-98205AE220F6Q39432209-880C6394-C424-47A8-A02F-FC31E389AE08Q41280874-9B06F566-3164-4361-821C-9F469C20920AQ41283940-BCFB153D-5DA0-4EE8-A003-4721B60BC056Q41634413-9BE3D8AB-9556-4DFC-9B93-8E2E77F1963DQ41656775-7041FD9D-3FD6-4CEE-B3DF-204377D005A1Q42084201-902EF83D-D0E3-4AF1-9A5D-DE81FC437E97Q42288326-F077F951-17E5-43F4-BAB2-7FCA72667584Q42361294-673E0C12-B28C-4D1F-A558-9240A3B094C7Q45976253-521450DE-B109-4FED-881F-9125F8F87FD2Q46058577-F9102302-24BC-45B0-B493-D0677E92913FQ47574118-1E009D37-40BE-4F10-BDAB-C5E8790066D1Q47666143-85491537-9016-46FA-A4D7-31DA67BC9449Q54217848-3BDB48C5-9C98-4B06-B8F1-585458F1209DQ55317641-3DAE0DEE-9CAF-4C81-8DB3-A7DB6B425419Q55324826-52C2B937-BA54-4D77-B99D-677AFF268729Q55364906-2BFA0DFB-A552-4DC4-9C4B-4679D360AFAFQ55438360-E3A17D67-02A6-44B0-9643-214B5132E032Q58749200-FFD312F8-4B04-45DF-A0C9-E0BA68636BD7
P2860
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@en
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@nl
type
label
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@en
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@nl
prefLabel
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@en
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@nl
P2093
P2860
P1433
P1476
Long-Acting Injectable Risperi ...... . A Randomized Clinical Trial.
@en
P2093
Denise Gretchen-Doorly
Gerhard S Hellemann
John S Luo
Joseph Ventura
Kenneth L Subotnik
Laurie R Casaus
Stephen Marder
P2860
P304
P356
10.1001/JAMAPSYCHIATRY.2015.0270
P407
P577
2015-08-01T00:00:00Z